keyword
MENU ▼
Read by QxMD icon Read
search

triple-negative breast cancer

keyword
https://www.readbyqxmd.com/read/28326836/clinical-significance-of-ndrg3-in-patients-with-breast-cancer
#1
Mehrdad Asghari Estiar, Ali-Akbar Zare, Rezvan Esmaeili, Leila Farahmand, Hassan Fazilaty, Davood Jafari, Tannaz Samadi, Keivan Majidzadeh-A
AIM: The expression level of NDRG3 gene is investigated among breast cancer (BC) patients. METHODS: Real-time quantitative PCR was performed. RESULTS:  NDRG3 was downregulated in BC patients particularly in advanced stage of the disease. HER2 status was significantly correlated with the expression of NDRG3. Also, triple-negative BC patients showed low levels of NDRG3 expression in comparison to other subtypes. Lastly, the expression of NDRG3 had significant impact on survival, with NDRG3 downregulated patients having the worst event-free survival rate among others...
February 27, 2017: Future Oncology
https://www.readbyqxmd.com/read/28325260/imaging-performance-in-guiding-response-to-neoadjuvant-therapy-according-to-breast-cancer-subtypes-a-systematic-literature-review
#2
REVIEW
Melanie A Lindenberg, Anna Miquel-Cases, Valesca P Retèl, Gabe S Sonke, Jelle Wesseling, Marcel P M Stokkel, Wim H van Harten
Monitoring therapeutic response to neoadjuvant chemotherapy(NAC) is likely to improve NAC effectiveness in breast cancer(BC). Imaging performance seems to vary per tumour subtype(by ER and HER2 status), therefore we performed a systematic review on subtype specific imaging performance in monitoring NAC in BC. Studies examining imaging performance in predicting pathologic complete response(pCR) during NAC in BC subtypes were selected. Per study, negative- and positive predictive value, sensitivity(se) and specificity(sp), AUC and accuracy were derived...
April 2017: Critical Reviews in Oncology/hematology
https://www.readbyqxmd.com/read/28325210/breast-cancer-immunology-and-immunotherapy-current-status-and-future-perspectives
#3
L de la Cruz-Merino, M Chiesa, R Caballero, F Rojo, N Palazón, F H Carrasco, V Sánchez-Margalet
Cancer immunology has gained renewed interest in the past few years due to emerging findings on mechanisms involved in tumoral immune evasion. Indisputably, immune edition is currently considered a critical hallmark of cancer. Basic research has revealed new targets which can be modulated in the clinical setting with new compounds and strategies. As recent evidence confirms, breast cancer (BC) is a complex and heterogeneous disease in which host immune responses play a substantial role. T-infiltrating lymphocytes measurement is suggested as a powerful new tool necessary to predict early BC evolution, especially in HER2-positive and triple negative subtypes...
2017: International Review of Cell and Molecular Biology
https://www.readbyqxmd.com/read/28324269/metformin-sensitizes-triple-negative-breast-cancer-to-proapoptotic-trail-receptor-agonists-by-suppressing-xiap-expression
#4
Elena Strekalova, Dmitry Malin, Harisha Rajanala, Vincent L Cryns
PURPOSE: Despite robust antitumor activity in diverse preclinical models, TNF-related apoptosis-inducing ligand (TRAIL) receptor agonists have not demonstrated efficacy in clinical trials, underscoring the need to identify agents that enhance their activity. We postulated that the metabolic stress induced by the diabetes drug metformin would sensitize breast cancer cells to TRAIL receptor agonists. METHODS: Human triple (estrogen receptor, progesterone receptor, and HER2)-negative breast cancer (TNBC) cell lines were treated with TRAIL receptor agonists (monoclonal antibodies or TRAIL peptide), metformin, or the combination...
March 21, 2017: Breast Cancer Research and Treatment
https://www.readbyqxmd.com/read/28320108/mir-103-regulates-triple-negative-breast-cancer-cells-migration-and-invasion-through-targeting-olfactomedin-4
#5
Bin Xiong, Xuefeng Lei, Lei Zhang, Jia Fu
Our previous study showed olfactomedin 4 (OLFM4) suppressed triple-negative breast cancer cells migration, invasion and metastasis-associated protein MMP 9 expression. OLFM4 was identified as a potential target of miR-103 according to microRNA target databases and published studies. The aim of this study is to validate the relationship between miR-103 and OLFM4, and explore the function and clinical significance of miR-103 in triple-negative breast cancer patients. In our results, miR-103 negatively regulated OLFM4 expression by directly targeting its 3'-UTR...
March 18, 2017: Biomedicine & Pharmacotherapy, Biomédecine & Pharmacothérapie
https://www.readbyqxmd.com/read/28319780/new-bis-hydroxymethyl-alkanoate-curcuminoid-derivatives-exhibit-activity-against-triple-negative-breast-cancer-in%C3%A2-vitro-and-in%C3%A2-vivo
#6
Min-Tsang Hsieh, Ling-Chu Chang, Hsin-Yi Hung, Hui-Yi Lin, Mei-Hui Shih, Chang-Hai Tsai, Sheng-Chu Kuo, Kuo-Hsiung Lee
Novel bis(hydroxymethyl) alkanoate curcuminoid derivatives were designed, synthesized and screened for in vitro antiproliferative and in vivo antitumor activity. Selected new compound 9a and curcumin were further evaluated for inhibitory activity against ER(+)/PR(+) breast cancer (MCF-7, T47D), HER 2(+) breast cancer (SKBR3, BT474, and MDA-MB-457) and triple negative breast cancer (TNBC) (HS-578T, MDA-MB-157, and MDA-MB-468) cell lines. In addition, compound 9a was evaluated in the MDA-MB-231 xenograft nude mice model...
March 8, 2017: European Journal of Medicinal Chemistry
https://www.readbyqxmd.com/read/28319069/the-branched-chain-amino-acid-transaminase-1-sustains-growth-of-antiestrogen-resistant-and-er%C3%AE-negative-breast-cancer
#7
V Thewes, R Simon, M Hlevnjak, M Schlotter, P Schroeter, K Schmidt, Y Wu, T Anzeneder, W Wang, P Windisch, M Kirchgäßner, N Melling, N Kneisel, R Büttner, U Deuschle, H P Sinn, A Schneeweiss, S Heck, S Kaulfuss, H Hess-Stumpp, J G Okun, G Sauter, A E Lykkesfeldt, M Zapatka, B Radlwimmer, P Lichter, M Tönjes
Antiestrogen-resistant and triple-negative breast tumors pose a serious clinical challenge because of limited treatment options. We assessed global gene expression changes in antiestrogen-sensitive compared with antiestrogen-resistant (two tamoxifen resistant and two fulvestrant resistant) MCF-7 breast cancer cell lines. The branched-chain amino acid transaminase 1 (BCAT1), which catalyzes the first step in the breakdown of branched-chain amino acids, was among the most upregulated transcripts in antiestrogen-resistant cells...
March 20, 2017: Oncogene
https://www.readbyqxmd.com/read/28315938/the-relationship-between-breast-cancer-molecular-subtypes-and-mast-cell-populations-in-tumor-microenvironment
#8
Anna Glajcar, Joanna Szpor, Agnieszka Pacek, Katarzyna Ewa Tyrak, Florence Chan, Joanna Streb, Diana Hodorowicz-Zaniewska, Krzysztof Okoń
Mast cells (MCs) are a part of the innate immune system. The MC functions toward cancer are partially based on the release of chymase and tryptase. However, the MC effect on breast cancer is controversial. The aim of our study was to investigate the presence of MCs in breast cancer tumors of different molecular subtypes and their relationships with other pathological prognostic factors. Tryptase- and chymase-positive mast cell densities were evaluated by immunohistochemistry in 108 primary invasive breast cancer tissue samples...
March 18, 2017: Virchows Archiv: An International Journal of Pathology
https://www.readbyqxmd.com/read/28315687/-10-gingerol-a-major-phenolic-constituent-of-ginger-root-induces-cell-cycle-arrest-and-apoptosis-in-triple-negative-breast-cancer-cells
#9
Megan M Bernard, Jason R McConnery, David W Hoskin
The ginger rhizome is rich in bioactive compounds, including [6]-gingerol, [8]-gingerol, and [10]-gingerol; however, to date, most research on the anti-cancer activities of gingerols have focused on [6]-gingerol. In this study, we compared [10]-gingerol with [8]-gingerol and [6]-gingerol in terms of their ability to inhibit the growth of human and mouse mammary carcinoma cells. A colorimetric assay based on the enzymatic reduction of 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide revealed that [10]-gingerol was more potent than [6]-gingerol and at least as potent as [8]-gingerol for the inhibition of triple-negative human (MDA-MB-231, MDA-MB-468) and mouse (4T1, E0771) mammary carcinoma cell growth...
March 16, 2017: Experimental and Molecular Pathology
https://www.readbyqxmd.com/read/28315068/efficacy-and-safety-of-nab-paclitaxel-125%C3%A2-mg-m-2-and-nab-paclitaxel-150%C3%A2-mg-m-2-compared-to-paclitaxel-in-early-high-risk-breast-cancer-results-from-the-neoadjuvant-randomized-geparsepto-study-gbg-69
#10
Jenny Furlanetto, Christian Jackisch, Michael Untch, Andreas Schneeweiss, Sabine Schmatloch, Bahriye Aktas, Carsten Denkert, Hermann Wiebringhaus, Sherko Kümmel, Mathias Warm, Stefan Paepke, Marianne Just, Claus Hanusch, John Hackmann, Jens Uwe Blohmer, Michael Clemens, Serban Dan Costa, Bernd Gerber, Valentina Nekljudova, Sibylle Loibl, Gunter von Minckwitz
PURPOSE: The GeparSepto study demonstrated that the use of nab-paclitaxel instead of paclitaxel prior to anthracycline-based chemotherapy could lead to a significantly increased pCR rate, especially in the triple negative subpopulation. We report efficacy and safety for patients treated with two different doses of nab-paclitaxel in comparison to weekly solvent-formulated paclitaxel. METHODS: Patients were treated for 12 weeks with either intravenous nab-paclitaxel 150 mg/m(2) (nP150) weekly, after study amendment 125 mg/m(2) (nP125) weekly or solvent-based paclitaxel 80 mg/m(2) (P80) weekly followed by epirubicin 90 mg/m(2) and cyclophosphamide 600 mg/m(2) on day 1 for four 3-week cycles...
March 17, 2017: Breast Cancer Research and Treatment
https://www.readbyqxmd.com/read/28315066/failure-patterns-according-to-molecular-subtype-in-patients-with-invasive-breast-cancer-following-postoperative-adjuvant-radiotherapy-long-term-outcomes-in-contemporary-clinical-practice
#11
Yu Jin Lim, Sea-Won Lee, Noorie Choi, Jeanny Kwon, Keun-Yong Eom, Eunyoung Kang, Eun-Kyu Kim, Sung-Won Kim, Jee Hyun Kim, Yu Jung Kim, Se Hyun Kim, So Yeon Park, Jae-Sung Kim, In Ah Kim
PURPOSE: Although gene expression profiling provides critical information, knowledge remains limited regarding the differential effects of molecular subtype on clinical course. This study evaluated the impact of molecular status on long-term patterns of failure in patients with non-metastatic breast cancer. METHODS: We analyzed data from 1181 individuals with invasive breast cancer undergoing surgery plus PORT from 2003 to 2011. Molecular subtypes were defined as luminal A (LA), luminal B (LB)-HER2(-), LB-HER2(+), HER2, and triple-negative (TN) based on the 2013 St...
March 17, 2017: Breast Cancer Research and Treatment
https://www.readbyqxmd.com/read/28314842/performance-of-mid-treatment-breast-ultrasound-and-axillary-ultrasound-in-predicting-response-to-neoadjuvant-chemotherapy-by-breast-cancer-subtype
#12
Rosalind P Candelaria, Roland L Bassett, William Fraser Symmans, Maheshwari Ramineni, Stacy L Moulder, Henry M Kuerer, Alastair M Thompson, Wei Tse Yang
BACKGROUND: The primary objective was to determine whether mid-treatment ultrasound measurements of index breast tumors and index axillary nodes of different cancer subtypes associate with residual cancer burden (RCB). METHODS: Patients with invasive breast cancer who underwent neoadjuvant chemotherapy and had pre-treatment and mid-treatment breast and axillary ultrasound were included in this single-institution, retrospective cohort study. Linear regression analysis assessed associations between RCB with (a) change in index breast tumor size, (b) change in index node size, and (c) absolute number of abnormal nodes at mid-treatment...
March 17, 2017: Oncologist
https://www.readbyqxmd.com/read/28314310/first-line-bevacizumab-and-paclitaxel-for-her2-negative-metastatic-breast-cancer-a-french-retrospective-observational-study
#13
Veronique Dieras, Simona Pop, Frederique Berger, Marie-Eglantine Dujaric, Philippe Beuzeboc, Laurence Escalup, François Clement Bidard, Paul Henri Cottu, Christophe LE Tourneau, Sophie Piperno-Neumann, Valerie Laurence, Mathieu Robain, Bernard Asselain, Jean-Yves Pierga
AIM: To assess outcomes in patients treated with first-line bevacizumab-containing therapy for human epidermal growth factor receptor (HER)2-negative metastatic breast cancer (mBC) at a single centre with a homogenous standard-of-care. PATIENTS AND METHODS: Information on patient and disease characteristics, efficacy, and safety was extracted from computer-based records of all patients receiving first-line bevacizumab-paclitaxel at the Curie Institute, Paris, France, between 2008 and 2011...
March 2017: Anticancer Research
https://www.readbyqxmd.com/read/28314283/stable-shrna-silencing-of-lactate-dehydrogenase-a-ldha-in-human-mda-mb-231-breast-cancer-cells-fails-to-alter-lactic-acid-production-glycolytic-activity-atp-or-survival
#14
Nzinga Mack, Elizabeth A Mazzio, David Bauer, Hernan Flores-Rozas, Karam F A Soliman
BACKGROUND: In the US, African Americans have a high death rate from triple-negative breast cancer (TNBC), characterized by lack of hormone receptors (ER, PR, HER2/ERRB2) which are otherwise valuable targets of chemotherapy. There is a need to identify novel targets that negatively impact TNBC tumorigenesis. TNBCs release an abundance of lactic acid, under normoxic, hypoxic and hyperoxic conditions; this referred to as the Warburg effect. Accumulated lactic acid sustains peri-cellular acidity which propels metastatic invasion and malignant aggressive transformation...
March 2017: Anticancer Research
https://www.readbyqxmd.com/read/28303998/mir-16-a-novel-hereditary-marker-in-breast-cancer-and-their-offspring
#15
Ambreen Usmani, Amir Ali Shoro, Bushra Shirazi, Zahida Memon, Mehvish Hussain
OBJECTIVE: To analyse micro ribonucleic acid-16 in sera of invasive intraductal breast carcinoma in stage III and compare its expression in their daughters and healthy women. METHODS: The study took place from January 2013 till December 2015. This case-control study was conducted at the Ziauddin Cancer Hospital, Karachi, and comprised breast cancer patients and healthy individuals. Stage III invasive intraductal breast cancer patients (cases), their age-matched healthy individuals (control group A) and patients' daughters (control group B) were included...
March 2017: JPMA. the Journal of the Pakistan Medical Association
https://www.readbyqxmd.com/read/28301662/brain-metastases-in-newly-diagnosed-breast-cancer-a-population-based-study
#16
Allison M Martin, Daniel N Cagney, Paul J Catalano, Laura E Warren, Jennifer R Bellon, Rinaa S Punglia, Elizabeth B Claus, Eudocia Q Lee, Patrick Y Wen, Daphne A Haas-Kogan, Brian M Alexander, Nancy U Lin, Ayal A Aizer
Importance: Population-based estimates of the incidence and prognosis of brain metastases at diagnosis of breast cancer are lacking. Objective: To characterize the incidence proportions and median survivals of patients with breast cancer and brain metastases at the time of cancer diagnosis. Design, Setting, and Participants: Patients with breast cancer and brain metastases at the time of diagnosis were identified using the Surveillance, Epidemiology, and End Results (SEER) database of the National Cancer Institute...
March 16, 2017: JAMA Oncology
https://www.readbyqxmd.com/read/28300203/corrigendum-parp-inhibitor-increases-chemosensitivity-by-upregulating-mir-664b-5p-in-brca1-mutated-triple-negative-breast-cancer
#17
Wei Song, Lin Tang, Yumei Xu, Jing Xu, Wenwen Zhang, Hui Xie, Shui Wang, Xiaoxiang Guan
No abstract text is available yet for this article.
March 16, 2017: Scientific Reports
https://www.readbyqxmd.com/read/28299888/the-relationship-of-race-oncotype-dx-and-ki67-in-a-population-highly-screened-for-breast-cancer
#18
Amber A Guth, Jennifer Chun Kim, Shira Schwartz, Jennifer Montes, Rebecca Akiko Snyder, Deborah Axelrod, Freya Schnabel
Oncotype DX recurrence score (ODX) can predict risk of invasive breast cancer recurrence and benefit of chemotherapy. Literature is limited on the relationship of ODX and race in women with hormone receptor positive and node negative/positive disease. Our study examines the relationship between race and clinical characteristics within a population of highly screened women with newly diagnosed breast cancer. The institutional Breast Cancer Database was queried for patients with newly diagnosed breast cancer between January2010 and March2015...
March 2017: Breast Journal
https://www.readbyqxmd.com/read/28299476/a-comparison-of-the-molecular-subtypes-of-triple-negative-breast-cancer-among-non-asian-and-taiwanese-women
#19
Ling-Ming Tseng, Jen-Hwey Chiu, Chun-Yu Liu, Yi-Fang Tsai, Yun-Lin Wang, Chu-Wen Yang, Yi-Ming Shyr
BACKGROUND: "Precision medicine" is a concept that by utilizing modern molecular diagnostics, an effective therapy is accurately applied for each cancer patient to improve their survival rates. The treatment of triple-negative breast cancer (TNBC) remains a challenging issue. The aim of this study was to compare the molecular subtypes of triple-negative breast cancer (TNBC) between Taiwanese and Non-Asian women. METHODS: GEO Datasets for non-Asian (12 groups, n = 1450) and Taiwanese (3 groups, n = 465) breast cancer, including 617 TNBC, were acquired, normalized and cluster analyzed...
March 15, 2017: Breast Cancer Research and Treatment
https://www.readbyqxmd.com/read/28298214/climat-het-detecting-subclonal-copy-number-alterations-and-loss-of-heterozygosity-in-heterogeneous-tumor-samples-from-whole-genome-sequencing-data
#20
Zhenhua Yu, Ao Li, Minghui Wang
BACKGROUND: Copy number alterations (CNA) and loss of heterozygosity (LOH) represent a large proportion of genetic structural variations of cancer genomes. These aberrations are continuously accumulated during the procedure of clonal evolution and patterned by phylogenetic branching. This invariably results in the emergence of multiple cell populations with distinct complement of mutational landscapes in tumor sample. With the advent of next-generation sequencing technology, inference of subclonal populations has become one of the focused interests in cancer-associated studies, and is usually based on the assessment of combinations of somatic single-nucleotide variations (SNV), CNA and LOH...
March 15, 2017: BMC Medical Genomics
keyword
keyword
54650
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"